Synopsys, a leading maker of software used to design computer chips, used its investor day in New York to cast itself as a central beneficiary of the artificial intelligence boom. The company raised its financial targets for fiscal 2027 and announced new partnerships with OpenAI and Amazon Web Services (AWS), including a licensing deal valued at more than $1 billion. Shares jumped on the news.
The message from management was straightforward: as AI models grow more powerful, the chips that run them become harder to design. That complexity, Synopsys argues, drives demand for its tools, which help engineers lay out and verify the billions of transistors on modern processors.
Higher targets, bigger ambitions
Synopsys now expects fiscal 2027 revenue of $11.10 billion to $11.20 billion, up from its previous outlook. It also lifted its earnings per share forecast to a range of $19.04 to $19.12. Both figures came in above the average analyst estimate tracked by LSEG, a data provider.
The company also said it plans to repurchase about $1 billion of its own stock over the coming months. Buybacks can support a company's share price by reducing the number of shares outstanding, and they signal that management believes the stock is undervalued.
Longer term, Synopsys is targeting roughly 15% annual revenue growth starting in fiscal 2028. That would be a step up from the growth rates many software companies have delivered in recent years, and it reflects the company's bet that AI will keep fueling demand for its products.
AI deals with OpenAI and AWS
The investor day also featured new commercial agreements. Synopsys unveiled a partnership with OpenAI, the creator of ChatGPT, and expanded its relationship with AWS, Amazon's cloud computing arm. The deals include a licensing agreement worth more than $1 billion, though the company did not break down how much of that total comes from each partner.
These are not just marketing tie-ups. Synopsys says its tools will be used to design the next generation of AI chips, and that its software will run on AWS's cloud infrastructure. The company has also been developing its own AI-powered features, such as a tool called GPT-Synopsys, which uses OpenAI's technology to help engineers write code and verify chip designs more quickly.
The broader context is that chip design has become one of the most complex engineering tasks in the world. A modern processor can contain tens of billions of transistors, and even small errors can be enormously costly. That complexity is why companies like Synopsys, along with rivals such as Cadence Design Systems, have been able to charge premium prices for their software.
What it means for investors
For everyday investors, the key takeaway is that Synopsys is positioning itself as a pick-and-shovel play on the AI boom. Rather than betting on which company's AI model will win, Synopsys sells the tools that all chipmakers need to build the hardware that powers AI.
The raised guidance suggests management is confident that demand will remain strong through 2027. The $1 billion buyback is a modest but positive signal, and the OpenAI and AWS deals add credibility to the company's AI story.
Still, there are risks. Synopsys's stock already trades at a high valuation, reflecting the market's optimism about AI. If the AI buildout slows, or if competition intensifies, the company could miss its ambitious targets. Investors should also note that the company's fiscal year ends in October, so the 2027 targets are roughly three years away.
For those watching the broader tech sector, Synopsys's investor day is another sign that AI spending is not just about data centers and cloud providers. The companies that make the design tools, manufacturing equipment, and testing software are also seeing a surge in demand. That theme has helped lift a range of tech stocks, including Hewlett Packard Enterprise, which also landed a multibillion-dollar AI deal recently.
The partnership with OpenAI is particularly notable because it shows how AI companies are moving beyond just using chips to actually influencing how they are designed. The two companies have already launched a product called GPT-Synopsys that aims to speed up chip design, and the new licensing deal suggests that relationship is deepening.
For investors, the main question is whether Synopsys can sustain its growth as the AI cycle matures. The company's guidance implies a high level of confidence, but it also sets a high bar. If the company delivers, shareholders could be rewarded. If not, the stock could face pressure given its premium valuation.
In the meantime, the investor day served its purpose: it reminded the market that Synopsys is not just a software company, but a key enabler of the AI revolution. Whether that translates into long-term shareholder value will depend on execution.
